MX2022003997A - Derivados de androstano con actividad como estimuladores puros o predominantemente puros de serca2a para el tratamiento de la insuficiencia cardiaca. - Google Patents

Derivados de androstano con actividad como estimuladores puros o predominantemente puros de serca2a para el tratamiento de la insuficiencia cardiaca.

Info

Publication number
MX2022003997A
MX2022003997A MX2022003997A MX2022003997A MX2022003997A MX 2022003997 A MX2022003997 A MX 2022003997A MX 2022003997 A MX2022003997 A MX 2022003997A MX 2022003997 A MX2022003997 A MX 2022003997A MX 2022003997 A MX2022003997 A MX 2022003997A
Authority
MX
Mexico
Prior art keywords
pure
serca2a
treatment
heart failure
stimulators
Prior art date
Application number
MX2022003997A
Other languages
English (en)
Inventor
Giuseppe Bianchi
Patrizia Ferrari
Mara Ferrandi
Paolo Barassi
Antonio Zaza
Marcella Rocchetti
Carlotta Ronchi
Shih-Che Hsu
Cerri, (Finado) Alberto
Francesco Peri
Andrea Luraghi
Eleonora Torre
Original Assignee
Windtree Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Windtree Therapeutics Inc filed Critical Windtree Therapeutics Inc
Publication of MX2022003997A publication Critical patent/MX2022003997A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0038—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an androstane skeleton, including 18- or 19-substituted derivatives, 18-nor derivatives and also derivatives where position 17-beta is substituted by a carbon atom not directly bonded to a further carbon atom and not being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se divulgan compuestos y composiciones para la activación de SERCA2a. En particular, se proporcionan compuestos que actúan como activadores de SERCA2a puros o predominantemente puros mientras que inhiben solamente de forma moderada la Na+/K+ATPase. En general, los compuestos divulgados son derivados de androstano que tienen la fórmula (I) (ver Fórmula) En el presente documento se divulgan también composiciones farmacéuticas que comprenden uno o más de los compuestos de fórmula (I) para su uso para el tratamiento de insuficiencia cardíaca.
MX2022003997A 2019-10-09 2020-10-08 Derivados de androstano con actividad como estimuladores puros o predominantemente puros de serca2a para el tratamiento de la insuficiencia cardiaca. MX2022003997A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19202257.2A EP3805243B1 (en) 2019-10-09 2019-10-09 Androstane derivatives with activity as pure or predominantly pure stimulators of serca2a for the treatment of heart failure
PCT/EP2020/078253 WO2021069570A1 (en) 2019-10-09 2020-10-08 ANDROSTANE DERIVATIVES WITH ACTIVITY AS PURE OR PREDOMINANTLY PURE STIMULATORS OF SERCA2a FOR THE TREATMENT OF HEART FAILURE

Publications (1)

Publication Number Publication Date
MX2022003997A true MX2022003997A (es) 2022-04-26

Family

ID=68242483

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003997A MX2022003997A (es) 2019-10-09 2020-10-08 Derivados de androstano con actividad como estimuladores puros o predominantemente puros de serca2a para el tratamiento de la insuficiencia cardiaca.

Country Status (15)

Country Link
US (1) US20230009312A1 (es)
EP (1) EP3805243B1 (es)
JP (1) JP2022551165A (es)
KR (1) KR20220079601A (es)
CN (1) CN114466855A (es)
AU (1) AU2020363865A1 (es)
BR (1) BR112022003915A2 (es)
CA (1) CA3149938A1 (es)
DK (1) DK3805243T3 (es)
ES (1) ES2970792T3 (es)
FI (1) FI3805243T3 (es)
IL (1) IL291412A (es)
MX (1) MX2022003997A (es)
PL (1) PL3805243T3 (es)
WO (1) WO2021069570A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114409726B (zh) * 2022-01-24 2023-07-04 东华大学 桦木醇环烯烃衍生物及其用途和制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1175219A (en) * 1967-06-22 1969-12-23 Ici Ltd 3-Aminoalkoxycarbonylmethylene Steroid Derivatives
US4534899A (en) 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
AU582122B2 (en) * 1983-08-02 1989-03-16 Research Corporation Steroids useful as anti-cancer,anti-obesity, anti-hyperglycemic,anti-autoimmune and anti-hyperchlesterolemic agents
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US6509006B1 (en) 1992-07-08 2003-01-21 Inhale Therapeutic Systems, Inc. Devices compositions and methods for the pulmonary delivery of aerosolized medicaments
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US5846743A (en) 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
ATE287703T1 (de) 1995-04-14 2005-02-15 Nektar Therapeutics Pulverförmige pharmazeutische formulierungen mit verbesserter dispergierbarkeit
US5716928A (en) 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US6007839A (en) 1996-02-16 1999-12-28 The Liposome Company, Inc. Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes
DE19633349A1 (de) * 1996-08-19 1998-02-26 Sigma Tau Ind Farmaceuti Neue 6-Hydroxy- und 6-Oxo-androstan-Derivate, die auf das kardiovaskuläre System wirken und pharmazeutische Zusammensetzungen, die diese enthalten
US5874268A (en) 1996-09-23 1999-02-23 Duke University Method of introducing exogenous compounds into cells by electroporation and apparatus for same
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
JP2000516641A (ja) 1997-07-02 2000-12-12 エスディージー インコーポレイテッド 診断および治療用途の目標指向性リポソーム構成物
SE9704076D0 (sv) 1997-11-06 1997-11-06 Holdingbolaget Vid Goeteborgs Method for permeabilisation of cell structures and use thereof
US6589503B1 (en) 1998-06-20 2003-07-08 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US20040151766A1 (en) 2003-01-30 2004-08-05 Monahan Sean D. Protein and peptide delivery to mammalian cells in vitro
WO2005063156A1 (en) 2003-12-22 2005-07-14 Shear/Kershman Laboratories, Inc. Oral peptide delivery system with improved bioavailability
EP1698329A4 (en) 2003-12-24 2009-10-28 Ltt Bio Pharma Co Ltd PHARMACEUTICAL NANOTEILS, METHOD FOR THE PRODUCTION THEREOF AND PARENTERALLY APPLIED PRODUCT FROM NANOTEILES
US8658203B2 (en) 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
JP4758915B2 (ja) 2004-08-06 2011-08-31 バイオスペクトラム，インコーポレイテッド 多重層リポソームおよびその製造方法
JP4959570B2 (ja) 2004-10-18 2012-06-27 日東電工株式会社 細胞内ペプチド送達
US9005654B2 (en) 2005-07-27 2015-04-14 Protiva Biotherapeutics, Inc. Systems and methods for manufacturing liposomes
ATE542570T1 (de) * 2006-01-31 2012-02-15 Univ Toledo Verwendung kardiotonischer steroiden als na/k- atpase liganden zur hautbehandlung
TWI392682B (zh) * 2006-04-13 2013-04-11 Sigma Tau Ind Farmaceuti 作為心血管疾病的治療藥物之雄甾烷和雄甾烯的胺基衍生物
TWI389917B (zh) * 2006-04-13 2013-03-21 Sigma Tau Ind Farmaceuti 作為心血管疾病治療藥物的雄甾烷與雄甾烯之氮雜環烷基衍生物
BRPI1012240A2 (pt) * 2009-03-23 2018-06-12 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. derivados de 5-beta, beta-14-androstana úteis para o tratamento de proteinúria, de glomeruloesclerose e de insuficiência renal
WO2014018375A1 (en) * 2012-07-23 2014-01-30 Xenon Pharmaceuticals Inc. Cyp8b1 and uses thereof in therapeutic and diagnostic methods
CN112118846B (zh) * 2019-03-05 2024-04-16 风树疗法公司 治疗急性心力衰竭(ahf)用的含伊司他肟的静脉内制剂

Also Published As

Publication number Publication date
KR20220079601A (ko) 2022-06-13
BR112022003915A2 (pt) 2022-08-23
EP3805243A1 (en) 2021-04-14
IL291412A (en) 2022-05-01
ES2970792T3 (es) 2024-05-30
CN114466855A (zh) 2022-05-10
PL3805243T3 (pl) 2024-03-18
WO2021069570A1 (en) 2021-04-15
EP3805243B1 (en) 2023-11-15
DK3805243T3 (da) 2024-01-02
TW202128182A (zh) 2021-08-01
JP2022551165A (ja) 2022-12-07
AU2020363865A1 (en) 2022-02-24
FI3805243T3 (fi) 2024-02-07
US20230009312A1 (en) 2023-01-12
CA3149938A1 (en) 2021-04-15

Similar Documents

Publication Publication Date Title
PH12020551315A1 (en) Benzoxazepin oxazolidinone compounds and methods of use
MY196582A (en) PD-1/PD-L1 Inhibitors
EP4026835A3 (en) Pd-1/pd-l1 inhibitors
MX2020010369A (es) Particulas implantables y metodos relacionados.
MX2022013612A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas.
MX2022007155A (es) Derivados de cromano novedosos que tienen actividad de degradacion de receptor de estrogeno y usos de los mismos.
MX2021009659A (es) Hidroxipiridoxazepinas como activadores de nrf2.
MX2022001004A (es) Inhibidores de enzimas.
MY135850A (en) Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use
EP4342473A3 (en) Compounds useful in hiv therapy
AU2020231934A8 (en) Compounds useful in HIV therapy
WO2018183370A3 (en) Kdm4 inhibitors
MX2020011986A (es) Composiciones que comprenden glucosa y hemicelulosa y su uso.
MX2022013396A (es) Compuestos de tetrahidroisoquinolina como activadores de nrf2.
MX2019011182A (es) Combinacion de derivados de isoindolinona con sgi-110.
IL186058A0 (en) Polymorphs of 3-0-(3',3' -dimethylsuccinyl) betulinic acid di-n-methyl-d-glucamine salt
MX2022003997A (es) Derivados de androstano con actividad como estimuladores puros o predominantemente puros de serca2a para el tratamiento de la insuficiencia cardiaca.
MX2015009348A (es) Composiciones hemostaticas.
ZA201908404B (en) 15.beta.-[3-propanamido]-substituted estra-1,3,5(10)-trien-17-one compounds and their 17-oximes for use in inhibition of 17.beta.-hydroxysteroid dehydrogenases
MX2023011057A (es) Derivados de indolina como inhibidores de receptores de dominio de discoidina 1 (ddr1) y receptores de dominio de discoidina 2 (ddr2).
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2022013398A (es) Compuestos de tetrahidroisoquinolina como activadores de nrf2.
TWI859343B (zh) 用於治療心臟衰竭的具有作為SERCA2a的純或顯著純刺激劑的活性的雄烷衍生物
MX2021012499A (es) Inhibidores mejorados del complejo de activación transcripcional notch y métodos para el uso de estos.
MX2020008082A (es) Compuestos y composiciones para el tratamiento del dolor.